Phase II Study of the Anti-Vascular Endothelial Growth Factor (alpha-VEGF) Monoclonal Antibody Bevacizumab in Combination With Fixed Dose Rate (FDR) Gemcitabine and Rapid-Fractionation Radiotherapy in the Pre-Operative Treatment of Potentially- Resectable Pancreatic Adenocarcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Gemcitabine
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 25 Sep 2018 Biomarkers information updated
- 18 Oct 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 18 Oct 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.